Drug updated on 11/16/2023
| Dosage Form | Drops (eye: 0.002% (20 mcg/mL)) |
| Drug Class | Recombinant human nerve growth factors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of neurotrophic keratitis.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Oxervate (cenegermin-bkbj) Prescribing Information. | 2019 | Dompé U.S. Inc., Boston, MA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Combined clinical and pharmacoeconomic report: cenergermin (Oxervate). | 2022 | CADTH |